|
C2ORF49 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.03210798083364E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.74630343308513E-11 |
| Normal-vs-Stage2 |
1.69420033557799E-13 |
| Normal-vs-Stage3 |
2.22366569602173E-12 |
| Normal-vs-Stage4 |
1.18409726468371E-11 |
| Stage1-vs-Stage2 |
1.317850E-02 |
| Stage1-vs-Stage3 |
3.948000E-02 |
| Stage1-vs-Stage4 |
1.847770E-01 |
| Stage2-vs-Stage3 |
2.541200E-01 |
| Stage2-vs-Stage4 |
1.780770E-01 |
| Stage3-vs-Stage4 |
7.251200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.22070131780561E-11 |
| Normal-vs-AfricanAmerican |
4.11439999847829E-08 |
| Normal-vs-Asian |
2.7838000016267E-08 |
| Caucasian-vs-AfricanAmerican |
8.873400E-01 |
| Caucasian-vs-Asian |
4.807000E-01 |
| AfricanAmerican-vs-Asian |
5.730000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.30704344517108E-13 |
| Normal-vs-Female |
1.46670453560205E-11 |
| Male-vs-Female |
4.260400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.75489955900332E-10 |
| Normal-vs-Age(41-60Yrs) |
3.32367466882033E-12 |
| Normal-vs-Age(61-80Yrs) |
3.05422354074381E-13 |
| Normal-vs-Age(81-100Yrs) |
3.63930000024659E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.673600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.870450E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.663400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.309200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.463400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.187800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.644400E-01 |
| Classical-VS-Follicular |
2.920600E-03 |
| Classical-VS-Other |
4.349200E-01 |
| Classical-VS-Normal |
2.11500039704049E-10 |
| Tall-VS-Follicular |
2.987200E-01 |
| Tall-VS-Other |
7.457400E-01 |
| Tall-VS-Normal |
8.49670001024094E-10 |
| Follicular-VS-Other |
8.324400E-01 |
| Follicular-VS-Normal |
1.63014046705712E-12 |
| Other-VS-Normal |
1.159130E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.26405569239796E-13 |
| Normal-vs-N1 |
9.92809945365991E-10 |
| N0-vs-N1 |
3.243400E-01 |
|
|
